NCT00405080 - A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 11, 2006

Primary Completion Date

January 5, 2007

Study Completion Date

January 5, 2007

Conditions

Nausea and Vomiting, Chemotherapy-Induced

Interventions

DRUG

GW679769 (Casopitant) oral tablets

Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.

DRUG

Rifampin oral capsules

Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.

Trial Locations (1)

98418

GSK Investigational Site, Tacoma